S OCAKÇI, G GÖRÜMLÜ, F SAHİN, N. ÖZSAN, O. ZEKİOĞLU, R. USLU, G SAYDAM

Occurence of chronic myeloid leukemia in two breast cancer survivors after 4 years

Aynı hastada 2 ayrı malinitenin es zamanlı saptanması çok nadir bir durumdur. Özellikle meme kanseri ya da Hodgkin lenfoma tanısı için kemoterapi ve/veya radyoterapi alan ve kür elde edilen insanlarda beklenen yasam süresi yeterince uzun olduğu için, bu tedavilere bağlı ikincil kanser görme sansı fazladır. Burada etiyolojik ajan olarak verilen kemoterapi ya da radyoterapi suçlanabilir. Ama aynı hastada 2 ayrı malinitenin es zamanlı saptanmasının mekanizması tam olarak aydınlatılamamıstır. Bu yazıda, meme kanseri ve kronik myeloid lösemi tanısı alan 2 olgu sunulmaktadır.

Meme kanseri tanısıyla izlenen iki olguda 4 yıl sonra kronik myeloid lösemi gelisimi

The coexistence of two different malignancies in the same patient is a very rare entity. It is highly possible to see secondary malignancies in survivors of cancer after chemotherapy or radiotherapy, especially in breast cancer and Hodgkin lymphoma since the life expectancy in these disorders is quite long. The drugs or the radiation given during the treatment could provide the etiopathological basis for development of secondary cancers. However, the exact mechanisms underlying the coexistence of two different cancers in the same patients have not yet been clarified. In this article, we summarize two patients with simultaneous breast cancer and chronic myeloid leukemia.

PDF

___

1. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD
2. Smith RE, Bryant J, DeCillis A et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicincyclophosphamide adjuvant therapy for operable brast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 2003; 21:1195-1204
3. Van Leeuwen FE, Travis LB. Second cancers. In: Devita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: Principles and practice of oncology, (2005)7th edn. Lippincott, Williams, and Wilkins, Philedelphia, PA
4. Preston DL, Kusumi S, Tomonaga M et al. Cancer incidence in atomic bomb survivors. Part III: Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res 1994; 37(suppl 2):S68–S97
5. Wingo PA, Tong T, Bolden S. Cancer statistics. Cancer J Clin 1997;45:8-30
6. Jemal A, Siegel R, Ward E et al (2006) Cancer statistics,. CA Cancer J Clin 2006;56:106-130
7. Howard RA, Gilbert ES, Chen BE, Hall P, Storm H, Pukkala E, Langmark F, Kaijser M, Andersson M, Joensuu H, Fossa SD, Travis LB. Leukemia following breast cancer: An international population-based study of 376,825 women. Breast Cancer Res Treat. 2007 ;105(3):359-68
8. Veronesi U, Boyle P, Goldhirsch A et al. Breast cancer. Lancet 2005; 365:1727–1741
9. Russell NS, Bartelink H. Radiotherapy: the last 25 years. Cancer Treat Rev 1999; 25:365–376
10. Honrado E, Benítez J, Palacios J.Mod Pathol. The molecular pathology of hereditary breast cancer: Genetic testing and therapeutic implications 2005;18(10):1305-20.
11. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N. Engl. J. Med. 344, 1031– 1037 (2001).
12. Shah NP and Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003; 22, 7389–7395
13. Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 2002;21, 8591–860
14. Lin J, ARlinghaus R. Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene 2008;27(32):4385-91
15. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I; EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data Lancet Oncol. 2007;8(9):784-96